Designing Inhibitors for the SARS CoV Main Protease as Anti-SARS Drugs
Severe Acute Respiratory Syndrome (SARS) is a serious respiratory illness reported in parts of Asia and Canada. A novel coronavirus (CoV) has been isolated and identified as the cause of the SARS for which there is currently no effective treatment. Given the epidemic, the rapid development of effica...
Main Authors: | Hamza Bari, Arif Ali Awan |
---|---|
Format: | Article |
Language: | English |
Published: |
McGill University
2020-12-01
|
Series: | McGill Journal of Medicine |
Subjects: | |
Online Access: | https://mjm.mcgill.ca/article/view/377 |
Similar Items
-
Differential Tropism of SARS-CoV and SARS-CoV-2 in Bat Cells
by: Susanna K.P. Lau, et al.
Published: (2020-12-01) -
Lack of Susceptibility to SARS-CoV-2 and MERS-CoV in Poultry
by: David L. Suarez, et al.
Published: (2020-12-01) -
Impact of a Nationwide Lockdown on SARS-CoV-2 Transmissibility, Italy
by: Giorgio Guzzetta, et al.
Published: (2021-01-01) -
Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August–October 2020
by: Sitanshu Sekhar Kar, et al.
Published: (2021-02-01) -
Analysis of SARS-CoV-2 Transmission in Different Settings, Brunei
by: Liling Chaw, et al.
Published: (2020-11-01)